Acorda Therapeutics, Inc. (Nasdaq: ACOR) has entered into a definitive agreement for the sale of all of its assets, including INBRIJA, AMPYRA, and FAMPYRA, to Merz Therapeutics for a total consideration of $185 million. This strategic move comes as Acorda, a prominent name in the pharmaceutical industry, seeks to navigate through Chapter 11 bankruptcy proceedings.…